Literature DB >> 25170110

ASXL genes and RUNX1: an intimate connection?

Klaus H Metzeler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25170110      PMCID： PMC4148754          DOI： 10.1182/blood-2014-07-586073

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

Authors:  M-T Krauth; C Eder; T Alpermann; U Bacher; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

2.  Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.

Authors:  Marta Pratcorona; Saman Abbas; Mathijs A Sanders; Jasper E Koenders; François G Kavelaars; Claudia A J Erpelinck-Verschueren; Annelieke Zeilemakers; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

3.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Authors:  Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

4.  The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.

Authors:  Robert Huether; Li Dong; Xiang Chen; Gang Wu; Matthew Parker; Lei Wei; Jing Ma; Michael N Edmonson; Erin K Hedlund; Michael C Rusch; Sheila A Shurtleff; Heather L Mulder; Kristy Boggs; Bhavin Vadordaria; Jinjun Cheng; Donald Yergeau; Guangchun Song; Jared Becksfort; Gordon Lemmon; Catherine Weber; Zhongling Cai; Jinjun Dang; Michael Walsh; Amanda L Gedman; Zachary Faber; John Easton; Tanja Gruber; Richard W Kriwacki; Janet F Partridge; Li Ding; Richard K Wilson; Elaine R Mardis; Charles G Mullighan; Richard J Gilbertson; Suzanne J Baker; Gerard Zambetti; David W Ellison; Jinghui Zhang; James R Downing
Journal:  Nat Commun       Date:  2014-04-08       Impact factor: 14.919

Review 5.  Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?

Authors:  Peter Paschka; Konstanze Döhner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

6.  RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Authors:  Jason H Mendler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Heiko Becker; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Jessica Kohlschmidt; Deedra Nicolet; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

7.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

8.  Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

Authors:  Jean-Baptiste Micol; Nicolas Duployez; Nicolas Boissel; Arnaud Petit; Sandrine Geffroy; Olivier Nibourel; Catherine Lacombe; Helene Lapillonne; Pascaline Etancelin; Martin Figeac; Aline Renneville; Sylvie Castaigne; Guy Leverger; Norbert Ifrah; Hervé Dombret; Claude Preudhomme; Omar Abdel-Wahab; Eric Jourdan
Journal:  Blood       Date:  2014-06-27       Impact factor: 22.113

Review 9.  Functional and cancer genomics of ASXL family members.

Authors:  M Katoh
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

10.  Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

Authors:  Omar Abdel-Wahab; Jie Gao; Mazhar Adli; Anwesha Dey; Thomas Trimarchi; Young Rock Chung; Cem Kuscu; Todd Hricik; Delphine Ndiaye-Lobry; Lindsay M Lafave; Richard Koche; Alan H Shih; Olga A Guryanova; Eunhee Kim; Sheng Li; Suveg Pandey; Joseph Y Shin; Leon Telis; Jinfeng Liu; Parva K Bhatt; Sebastien Monette; Xinyang Zhao; Christopher E Mason; Christopher Y Park; Bradley E Bernstein; Iannis Aifantis; Ross L Levine
Journal:  J Exp Med       Date:  2013-11-11       Impact factor: 14.307
  10 in total
  3 in total

1.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Authors:  Nicolas Duployez; Alice Marceau-Renaut; Nicolas Boissel; Arnaud Petit; Maxime Bucci; Sandrine Geffroy; Hélène Lapillonne; Aline Renneville; Christine Ragu; Martin Figeac; Karine Celli-Lebras; Catherine Lacombe; Jean-Baptiste Micol; Omar Abdel-Wahab; Pascale Cornillet; Norbert Ifrah; Hervé Dombret; Guy Leverger; Eric Jourdan; Claude Preudhomme
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

2.  De Novo Truncating Variants in ASXL2 Are Associated with a Unique and Recognizable Clinical Phenotype.

Authors:  Vandana Shashi; Loren D M Pena; Katherine Kim; Barbara Burton; Maja Hempel; Kelly Schoch; Magdalena Walkiewicz; Heather M McLaughlin; Megan Cho; Nicholas Stong; Scott E Hickey; Christine M Shuss; Michael S Freemark; Jane S Bellet; Martha Ann Keels; Melanie J Bonner; Maysantoine El-Dairi; Megan Butler; Peter G Kranz; Constance T R M Stumpel; Sylvia Klinkenberg; Karin Oberndorff; Malik Alawi; Rene Santer; Slavé Petrovski; Outi Kuismin; Satu Korpi-Heikkilä; Olli Pietilainen; Palotie Aarno; Mitja I Kurki; Alexander Hoischen; Anna C Need; David B Goldstein; Fanny Kortüm
Journal:  Am J Hum Genet       Date:  2016-09-29       Impact factor: 11.025

3.  Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.

Authors:  Diego Carbonell; Julia Suárez-González; María Chicano; Cristina Andrés-Zayas; Juan Carlos Triviño; Gabriela Rodríguez-Macías; Mariana Bastos-Oreiro; Patricia Font; Mónica Ballesteros; Paula Muñiz; Pascual Balsalobre; Mi Kwon; Javier Anguita; José Luis Díez-Martín; Ismael Buño; Carolina Martínez-Laperche
Journal:  Cancers (Basel)       Date:  2019-09-13       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.